Serum magnesium, mortality and disease progression in chronic kidney disease
Rami Azem(Cleveland Clinic), Georges N. Na khoul(Cleveland Clinic), Jesse D. Schold(Colorado School of Public Health), Rémy Daou(Saint Joseph University), Elias Bassil(Cleveland Clinic), Tushar J. Vachharajani(Cleveland Clinic), Jonathan J. Taliercio(Cleveland Clinic), Joseph V. Nally(Cleveland Clinic), Eva Maria Anvari(Cleveland Clinic), Susana Arrigain(Cleveland Clinic)
Cited by 50
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
|The Lancet Diabetes & Endocrinology|2019|330
Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
|Journal of the American Society of Nephrology|2019|209
Masked Hypertension and Elevated Nighttime Blood Pressure in CKD
|Clinical Journal of the American Society of Nephrology|2016|197
Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease
|Clinical Journal of the American Society of Nephrology|2011|181